gg. Suggest you chk them out Remember MDCO .....well finally
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year Wed, December 22, 2021, 1:22 PM·10 min read - With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1)
- Leqvio provides effective and sustained LDL-C reduction of up to 52% vs. placebo for certain people with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin therapy(2,3)
- Approximately 16 million Americans with ASCVD taking statins to lower cholesterol--including those who have experienced a heart attack or stroke--are not at recommended LDL-C target(4,5)
By the way PCSK9's and Vascepa go well together
So for all U out there that dislike or poorly tolerate statins ......Let me introduce U to a PCSK9i ...One shot delivered sub Q in a clinic and then 6 mths later get your second sub Q shot ...timed the same day as your annual flu shot .